Song E K, Yeom J-H, Shin H T, Kim S H, Shin W G, Oh J M
Department of Pharmacy, Sejong General Hospital, Seoul, Korea.
J Clin Pharm Ther. 2006 Oct;31(5):421-7. doi: 10.1111/j.1365-2710.2006.00753.x.
To evaluate the effect of raloxifene on bone mineral density (BMD) and serum lipid levels in post-menopausal women who had discontinued hormone replacement therapy (HRT).
Thirty-four post-menopausal women with low BMD who had taken 60 mg of raloxifene daily for 12 months after discontinuing HRT were evaluated retrospectively. Information about their demographics, fracture history, BMD, lipid profiles and adverse events were collected from medical records and intranet database. The outcome measures were changes in the spine (L2-L4) and femur BMD, serum lipid concentrations, fracture rate and tolerability.
The post-menopausal women had a significant increase in their spine (L2-L4) and femur BMD from their baseline BMD [spine, 2.9 +/- 4.6% (P < 0.001); femur, 3.0 +/- 6.6% (P = 0.01)]. Serum low-density lipoprotein (LDL) cholesterol was significantly reduced by 22.6% below baseline after 12 months (P = 0.007). No fractures were observed during therapy. Raloxifene was well tolerated. The most common adverse event was hot flash, which was generally mild.
Raloxifene increases BMD at important skeletal sites, and lowers LDL cholesterol with tolerable adverse events.
评估雷洛昔芬对已停用激素替代疗法（HRT）的绝经后女性骨矿物质密度（BMD）和血脂水平的影响。
回顾性评估34名绝经后BMD较低的女性，她们在停用HRT后每天服用60mg雷洛昔芬，持续12个月。从病历和内部网络数据库中收集她们的人口统计学信息、骨折史、BMD、血脂谱和不良事件。观察指标为脊柱（L2-L4）和股骨BMD的变化、血脂浓度、骨折发生率和耐受性。
绝经后女性的脊柱（L2-L4）和股骨BMD较基线BMD有显著增加[脊柱，2.9±4.6%（P<0.001）；股骨，3.0±6.6%（P=0.01）]。12个月后，血清低密度脂蛋白（LDL）胆固醇较基线水平显著降低22.6%（P=0.007）。治疗期间未观察到骨折。雷洛昔芬耐受性良好。最常见的不良事件是潮热，一般程度较轻。
雷洛昔芬可增加重要骨骼部位的BMD，并降低LDL胆固醇，不良事件耐受性良好。
Zotero 插件